Matt Angel, Ph.D.
Co-Founder, Chairman and CEO
Matt has led Factor Bioscience since its founding in 2011. He received his bachelor’s degree in engineering from Princeton University in 2003, and later that year joined the Biodefense Systems Group at Lincoln Laboratory. Matt completed his Ph.D. at MIT in 2011, focusing on the study of protein expression and innate immunity. In addition to coordinating Factor’s business and intellectual-property strategies, Matt leads Factor’s efforts to pioneer new applications of our core technologies.
Christopher Rohde, Ph.D.
Chris joined Factor after completing his Ph.D. at MIT in early 2012. Chris has extensive experience developing technologies for high-throughput and high-content screening. His work is described in numerous peer-reviewed publications, and has been covered by Technology Review, Nature, Bioscience Magazine, Analytical Chemistry, The Economist, and many others. Chris is currently leading Factor’s efforts to apply our RiboSlice™ gene-editing technology, and FactorStem™ reprogramming and differentiation technologies to the development of new research models, including high-throughput screening-compatible human cell libraries, for the study and treatment of Alzheimer’s disease.